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ABSTRACT
The antitumour antibiotic mithramycin A (MTA) is a
DNA minor-groove binding ligand. It binds to
C/G-rich tracts as a dimer that forms in the
presence of divalent cations such as Mg2þ.
Differential scanning calorimetry, UV thermal
denaturation, isothermal titration calorimetry and
competition dialysis were used, together with
computations of the hydrophobic free energy of
binding, to determine the thermodynamic profile of
MTA binding to DNA. The results were compared to
those obtained in parallel using the structurally
related mithramycin SK (MSK). The binding of MTA
to salmon testes DNA determined by UV melting
studies (Kobs¼ 1.2 (0.3) 105 M1) is tighter than
that of MSK (2.9 (1.0)104 M1) at 258C.
Competition dialysis studies showed a tighter MTA
binding to both salmon testes DNA (42% CþG) and
Micrococcus lysodeikticus DNA (72% CþG). The
thermodynamic analysis of binding data at 258C
shows that the binding of MTA and MSK to DNA is
entropically driven, dominated by the hydrophobic
transfer of the antibiotics from solution to the
DNA-binding site. Direct molecular recognition
between MTA or MSK and DNA through hydrogen
bonding and van der Waals contacts may also
contribute significantly to complex formation.
INTRODUCTION
Mithramycin A (MTA), also known as plicamycin, is an
antitumour antibiotic used clinically in the treatment of
Paget’s disease and testicular carcinoma (1), and it has
gained renewed attention as a therapeutic agent in both
cancer- and non-cancer-related pathologies (2,3). MTA
(Figure 1) and the structurally related chromomycin
A3 and olivomycin are members of the aureolic group
of antitumour antibiotics. All contain the same tricyclic
core moiety, with a unique dihydroxy-methoxy-oxo-
pentyl side chain attached at C-3. They vary only slightly
with respect to the residue at C-7, which can be either an
H atom or a small alkyl side chain. However, these
antibiotics diﬀer in the nature of their saccharide
chains, which consist of several 2,6-dideoxysugar residues
(4,5). The mithramycin biosynthetic pathways have been
almost completely elucidated (6–9). Mithramycin SK
(MSK) is a secondary metabolite of MTA, which bears
a butyl instead of a pentyl chain, and the functional keto
and alcohol groups are in diﬀerent positions (Figure 1).
MSK has been generated by insertional inactivation
of gene mtmW in Streptomyces argillaceus (8). It has
been tested in vitro against several human cancer cell lines,
showing an improved therapeutic index compared to
MTA (8), in addition to inhibiting transcription of several
genes (10).
The primary cellular target of these molecules is DNA,
while bivalent cations such as Mg2þ are an essential
requirement for their binding to DNA (11–14), which
occurs along the minor groove of C/G-rich tracts
(4,12,13,15,16). Mg2þ-coordinated MTA dimers bind in
the minor groove of DNA, with the chromophores
parallel to the sugar-phosphate backbone and the
saccharide chains partially wrapping the DNA minor
groove (16). Equilibrium and kinetic studies indicate that
MTA forms two types of complex with magnesium, which
are referred to as Complex I (with 1:1 MTA:Mg2þ
stoichiometry) and Complex II (2:1 MTA:Mg2þ stoichio-
metry) (12,17). In Complex II, the metal ion binds to
the two oxygen atoms of each chromophore, while
two water molecules are involved as the ﬁfth and sixth
ligands (14). Upon binding to DNA, the chromophores
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form hydrogen bonds with the NH2 of guanines, thus
determining the selectivity for C/G-rich sequences
(4,14,16). Because of this sequence selectivity, MTA
blocks the binding of the Sp1 family of transcription
factors to C/G-rich sequences in gene promoters and
inhibits gene transcription (10,18,19), which in turn alters
the regulation of cell proliferation and diﬀerentiation
(10,19–21).
Here, we present the ﬁrst attempt at direct thermo-
dynamic characterization of binding in the minor groove
of C/G-regions of DNA without intercalation, using
direct calorimetric measurements of the interaction of
MTA and MSK with DNA. To date, only the binding in
the minor groove of AT-rich DNA has been thermo-
dynamically characterized in detail (22–25), while there
are some grounds to consider that binding to DNAs of
diﬀerent nucleotide composition might result in changes
in the enthalpy and entropy components of binding (26).
Hence, a thermodynamic comparison of the binding
of minor-groove ligands to diﬀerent base-pairs is still
required. Furthermore, the binding of MTA and MSK is
challenging because of the formation of a drug-dication
complex (17), which is required for the interaction with
DNA. We report direct measurements of the enthalpy of
binding to salmon testes DNA, which allowed us to
calculate the entropic and enthalpic contributions to the
free energy of binding. For MTA, using isothermal
titration calorimetry (ITC), the binding enthalpy and the
apparent binding constant can be directly determined
without invoking the van’t Hoﬀ relationship. We have
characterized the hydrophobic component of binding
(Ghyd) for both mithramycins by using a calculation
of the solvent-accessible area in mithramycin–DNA
complexes, since it was not feasible to measure any
heat capacity (Cp) eﬀect experimentally. Finally,
competition dialysis, which provides a simple and direct
quantitative measure of sequence selectivity (27), was
used to characterize the diﬀerences in the binding of
MTA and MSK to DNAs of various nucleotide
compositions. We aimed to extend our understanding
of the binding in the minor groove of C/G-rich DNAs,
which may ultimately be of pharmacological interest in
the pursuit of enhancing the DNA-binding capabilities of
synthetic molecules.
MATERIALS AND METHODS
Materials
MTA and its secondary metabolite MSK (Figure 1) were
isolated and puriﬁed from the producing organisms as
described previously (7,8). Stocks of MTA or MSK were
prepared as 3mM solutions in 20mM Hepes (pH7.4)
supplemented with NaCl to obtain the ﬁnal Naþ
concentrations used in the experiments. Except where
otherwise indicated, the buﬀer used throughout (desig-
nated HPS buﬀer) contained 150mMNaCl, 20mMHepes
(pH7.4). Molar extinction coeﬃcients of 10 000M1 cm1
at 400 nm and of 10 600 M-1 cm-1 – at 420 nm were used
to determine the concentration of MTA and MSK,
respectively (8,12).
Salmon testes DNA (Sigma) and Micrococcus
lysodeikticus DNA (Sigma) were dissolved in 10mM
NaCl, 20mM Hepes (pH7.4), sonicated, phenol extracted
twice and extensively dialysed against 20mM Hepes
(pH7.4) containing various NaCl concentrations.
Poly[d(G-C)2] (Amersham Biosciences) and poly[d(I-C)2]
(Roche) were dissolved in HPS buﬀer and extensively
dialysed against the same buﬀer.
DNA concentrations, in base pairs, were determined
spectrophotometrically by using the following molar extinc-
tion coeﬃcient (M1 cm1) values (28): "260(salmon testes
DNA)¼ 12824, "260(M. lysodeikticus DNA)¼ 13846,
"254(poly[d(G-C)2])¼ 16800 and "251(poly[d(I-C)2])¼ 13800.
Continuous variation binding analysis
The stoichiometry for the binding of MTA and MSK to
salmon testes DNA was obtained in HPS buﬀer using
the method of continuous variation (29). The concentra-
tions of either MTA or MSK and DNA were each
varied, while the sum of the concentrations was kept
constant at 40 mM. Varying volumes of equally concen-
trated stock solutions of the antibiotics and DNA were
mixed to give a mole fraction of ligands ranging from
0 to 0.3. The MgCl2 concentration was double the
antibiotic concentrations in all the experiments to
ensure the formation of Mg2þ-coordinated drug dimers
(2:1 MTA:Mg2þ stoichiometry) (12). The diﬀerence in
absorbance (A400 nm for MTA or A420 nm for
MSK) was plotted against the molar fraction of
antibiotic.
Figure 1. Structural formulae of mithramycin A and mithramycin SK.
2216 Nucleic Acids Research, 2007, Vol. 35, No. 7
Ultraviolet melting studies and differential scanning
calorimetry
Ultraviolet (UV) DNA melting curves were determined
using a Jasco V-550 spectrophotometer (Jasco), equipped
with an ETC-505T (Jasco) temperature controller.
Sonicated salmon testes DNA in 20mM Hepes (pH7.4)
was used for melting studies, in the presence of various
concentrations of NaCl, ranging from 10 to 150mM.
Samples contained 20 mM (bp) DNA, 7 mM MTA or
MSK (a concentration enough to saturate the nucleic acid)
and 14 mM MgCl2 to obtain Mg
2þ-coordinated drug
dimers (12). The samples were equilibrated at 258C for
30min and then heated at a rate of 18Cmin1, while
continuously monitoring the absorbance at 260 nm.
The Spectra Manager software (Jasco) was used to
analyse the data and to calculate the DNA melting
temperature (Tm).
Diﬀerential scanning calorimetry (DSC) measure-
ments were performed using a MicroCal MC-2
Scanning Calorimeter. Sonicated salmon testes DNA
was dissolved in HPS buﬀer, and extensively dialysed
against the same buﬀer. Samples of MTA or MSK for
DSC were prepared by mixing appropriate solutions of
either antibiotic and MgCl2 to a 1:2 molar ratio in
HPS buﬀer. In a standard experiment, the antibiotic–
DNA complexes consisted of 0.15mM antibiotic,
0.30mM MgCl2 (i.e. a pre-formed Mg
2þ-coordinated
antibiotic dimer) and 0.7mM DNA. After equilibration
for 2–3 h in the dark, any undissolved antibiotic
was removed by low-speed centrifugation. The amount
of drug bound to the DNA was determined spectro-
photometrically (12). A heating rate of 0.58Cmin1 was
used. Primary data were corrected by subtraction of a
buﬀer–buﬀer baseline, normalized to the concentration
of DNA (in bp), and further baseline-corrected. Data
acquisition (excess heat capacity versus temperature)
and analysis were performed using the Origin software
(MicroCal).
The DSC results and UV melting studies were used
to calculate the binding constant of MTA and MSK
binding to salmon testes DNA at the DNA melting
temperature ðKTm Þ, using the equation derived by
Crothers (30):
1=T

m  1=Tm ¼ ðR=nHwcÞln ð1þ KTmaÞ ð1Þ
where T

m(kelvin) is the UV melting temperature of
salmon testes DNA alone, Tm (kelvin) is the melting
temperature in the presence of saturating amounts of
the drug, Hwc is the enthalpy of DNA melting obtained
by DSC, R is the gas constant, KTm is the drug binding
constant at Tm, a is the free drug activity, which is
estimated by one-half of the total drug concentration and
n is the size of the drug-binding site determined by
continuous variation analysis, as described above.
The calculated apparent binding constant at Tm can be
extrapolated to lower temperatures by use of the van’t
Hoﬀ equation:
ln K=KTm
  ¼  Hb=Rð Þ 1=T 1=Tmð Þ ð2Þ
where K is the DNA binding constant of MTA or MSK at
temperature T (kelvin) and Hb is the enthalpy of binding
of the antibiotics to DNA determined by DSC.
The experimental Kobs, calculated at 258C, and the
binding enthalpy for MTA and MSK binding to DNA
allowed us to obtain complete thermodynamic proﬁles.
Free energies were calculated from the standard
relation G8¼RT ln Kobs and the entropy was eval-
uated using the standard thermodynamic relationship:
S8¼ (H8G8)/T.
Salt dependence of the binding constant
Diﬀerences between the DNA melting temperatures of
DNA alone and in the presence of saturating amounts
of MTA or MSK at diﬀerent NaCl concentrations, in
the presence of MgCl2, were used to calculate DNA
binding constants for MTA and MSK at the melting
temperature. These DNA binding constants were
corrected to 258C by application of Equation (2),
assuming that the binding enthalpy is independent of
salt concentration. These data can be analysed using the
polyelectrolyte theory of Record et al. (31) considering:
 logKð Þ= log Naþ   ¼ ðZ Þ ð3Þ
The Z value is equivalent to the number of counter-
ions released upon binding, which can be used to evaluate
the polyelectrolyte contribution to the free energy of
binding to salmon testes DNA using the relationship:
Gpe ¼ ðZ ÞRT ln½Na ð4Þ
and the Gpe values were used to calculate Gt: the
‘non-polyelectrolyte contribution to binding’ using the
following equation:
Gt ¼ Gobs Gpe ð5Þ
Isothermal titration calorimetry
Experiments were carried out at 258C using a MicroCal
MCS-ITC calorimeter, and the Origin 2.9 software
(MicroCal) was used for data acquisition and analysis.
In a typical experiment, 1.34ml of 0.50mM (bp) DNA
was titrated using a 2mM antibiotic solution in HPS
buﬀer, containing 4mM MgCl2 (40 injections of 5 ml
each), using a 250 ml syringe rotating at 400 r.p.m.
The injection time was 12 s, and the delay between
injections was 4min. The peaks produced during titration
were converted to heat output per injection by integ-
ration and correction for the cell volume and sample
concentration. Heat of dilution corrections were per-
formed for the injections of Mg2þ–antibiotic complex into
buﬀer. Moreover, we titrated MgCl2 into DNA, both
prepared as solutions in HPS buﬀer to measure the heat of
dilution produced by magnesium, in amounts equivalent
to those used in the presence of the antibiotics {i.e. the
amount of magnesium needed to obtain dimers of
the antibiotics [Complex II, (12)]}. Under these experi-
mental conditions the ﬁnal Mg2þ concentration was
0.5mM. We also measured the heat change induced in
the formation of Mg2þ–antibiotic complexes by the
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titration of a 1.5mM antibiotic solution in HPS buﬀer
into a 0.5mM MgCl2 solution in the same buﬀer.
Binding enthalpy (H), the stoichiometry (n) and the
binding constant (K) were obtained by ﬁtting the corrected
data to a model incorporated in the Origin 2.9 software,
which considers a single set of identical binding sites.
Calculation of solvent-accessible surface areas
We applied the method described by Haq et al. (32) to
estimate the hydrophobic contribution (Ghyd) to the
drug–DNA-binding free energy from the change in
solvent-accessible surface area upon complex formation.
To this end, we used the coordinates from PDB entry
146D (16) for the DNA–MTA complex. In this structure,
a Mg2þ-coordinated MTA dimer is bound to the
d(TCGCGA) duplex DNA sequence. For MSK, a model
was built manually from the structure of MTA in this
complex. Force-ﬁeld parameters for MTA and MSK were
obtained from the PRODRG2 server and adapted to the
Amber-99 force ﬁeld in GROMACS (33). Parameters for
the DNA part of the complex were obtained for the same
force ﬁeld directly from GROMACS. An ideal B-DNA
model of the same sequence was generated using the
3DNA program (34) to account for the unbound
structure. The free structures of MTA and MSK were
regarded as their Mg2þ-coordinated dimers. Models of
complexes and free molecules were subjected to molecular
mechanics energy minimization in GROMACS, using the
steepest descent method. The resulting coordinates were
used for the energy calculations described below.
Accessible surface areas were computed using the
analytical method within the NACCESS 2.1.1 program
(35). The van der Waals atomic radii used were those
deﬁned by Chothia (36) and the probe radius was 1.4 A˚.
Surfaces of carbon, carbon-bound hydrogen and phos-
phorus atoms were deﬁned as non-polar, whereas those of
all other atoms were considered as polar (32).
The change in solvent-accessible surface area (SASA)
on binding is the diﬀerence between the area of a given
complex and the sum of the surface areas of the drug-free
native duplex and the ligand molecule separated from each
complex. Heat capacity change (Cp) values were
calculated using the relationship (37):
Cp ¼ ð0:32 0:04ÞAnp
 ð0:14 0:04ÞAp cal mol1 K1
where Anp and Ap are the binding-induced accessible
surface area changes, in units of A˚2, in non-polar and polar
surfaces area, respectively. From these values, we estimated
the hydrophobic contribution to the antibiotic–DNA-
binding free energy using the empirical relationship (38):
Ghyd ¼ 80ð  10ÞCp kcal mol1
Competition dialysis assays
Competition dialysis assays were carried out as described
elsewhere (27), with minor modiﬁcations. The HPS
buﬀer was used for all experiments. A volume of 0.2ml
(75 mM in bp) of each of the DNA samples, described
above, was introduced into separate Slice-A-Lyzer mini
dialysis units (Pierce, Rockford, IL). For each competition
dialysis assay, all the dialysis units were placed in a beaker
containing the dialysate solution, consisting of 200ml of
1 mM ligand and 4 mM MgCl2 in the same buﬀer. The
dialysis was allowed to equilibrate, with continuous
stirring, for 24 h at 25 18C in the dark. At the end of
the equilibration period, DNA samples were removed to
microfuge tubes, and were taken to a ﬁnal concentration
of 1% (w/v) sodium dodecyl sulfate (SDS). The total
concentration of drug (Ct) within each dialysis unit was
then determined spectrophotometrically using wave-
lengths and extinction coeﬃcients appropriate for MTA
and MSK (see above). The free ligand concentration (Cf),
which did not vary appreciably from the initial concentra-
tion of 1 mM, was determined spectrophotometrically
using an aliquot of the dialysate solution. The amount
of bound drug was determined by diﬀerence: Cb¼CtCf.
The apparent binding constant for any DNA can be
calculated from the competition dialysis assays (39) by
using the following relationship:
Kapp¼Cb=Cf Ct  Cbð Þ
where Cb is the drug bound, Cf is the free drug
concentration (maintained at 1 mM in the assay) and
Ct is the total nucleic acid concentration (75 mM in the
assay protocol).
RESULTS
Using the method of continuous variation (Job plots)
we determined that the binding of MTA or MSK to
salmon testes DNA corresponds approximately to 1:5
(antibiotic:DNA in bp) stoichiometry (Figure S1),
in agreement with previous NMR results that showed
MTA binding to about 5–6 bp in the minor groove of a
double-strand oligonucleotide (4,13).
Determination of the DNA binding constant ofMTA and
MSK by UVmelting studies
UV melting studies and DSC were used to determine the
binding constant for the interaction of MTA and MSK
with salmon testes DNA. In the absence of either
antibiotic, the Tm of salmon testes DNA was 88.48C. In
the presence of a concentration of MTA or MSK suﬃcient
to saturate the DNA lattice, the Tm were 91.0 and 89.58C,
respectively (Figure S2). The enthalpy of DNA melting in
the absence of ligand (Hm) was determined by DSC to
be 8.60 (0.31) kcalmol1 (bp) (Figure 2). These values
were used to determine the DNA binding constant at the
melting temperature by using Equation (1), yielding
KTm ¼ 1:5 105M1 for MTA and 5.7 104M1 for
MSK. Correction of these values to lower temperature
requires knowledge of the binding enthalpy, which we also
determined by DSC, as follows.
Figure 2 shows the results of DSC experiments using
salmon testes DNA in the presence and absence of
saturating amounts of MTA or MSK, in the presence of
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MgCl2 (a Mg
2þ–antibiotic complex, see Materials and
methods section). By Hess’s law, these data may be
used to determine the enthalpy of ligand binding to
DNA as described elsewhere (40,41). From three
independent determinations, we obtained a Hb of
þ1.60 0.32 kcalmol1for the association of MTA to
DNA, while the Hb for the association of MSK was
þ1.02 0.33 kcalmol1. In both cases, enthalpy values
refer to the temperature of their respective Tm.
Once the binding enthalpy was determined, we calcu-
lated, by application of Equation (2), the DNA binding
constant (Kobs) of MTA and MSK at 258C to be 1.2
(0.3) 105M1 and 2.9 (1.0) 104M1, respectively.
Knowledge of the binding constant and binding enthalpy
allowed us to construct and compare the complete
thermodynamic proﬁles (G, H and S) for the binding
of MTA and MSK to salmon testes DNA (Table 1). The
sign of the thermodynamics parameters indicates unam-
biguously that binding of MTA and MSK to DNA was
entropically driven (Table 1).
Diﬀerences between the DNA melting temperatures of
DNA alone and in the presence of saturating amounts of
MTA or MSK at diﬀerent millimolar concentrations of
NaCl (Figure S2) were used to calculate DNA binding
constants at various ionic strengths, at 258C, as described
above. Figure 3 shows the dependence of the binding
constant at 258C on the concentration of Naþ. The
binding constants for both antibiotics decreased slightly
with increasing salt concentrations. In the presence of
30mM Naþ, the binding constants calculated for MTA
and MSK at 258C were 2.4 (0.5) 105M1 and
5.7 (1.3) 104M1 respectively, which were, as
expected, higher than those in the presence of 170mM
Naþ. These salt-dependent data for minor-groove-binding
ligands can be analysed using the polyelectrolyte theory of
Record et al. (31). From that theory, the slopes of the
lines in Figure 3 are equivalent to the number of Naþ
counterions released upon binding of a ligand. For MTA
and MSK, we found that 0.37 and 0.40 counterions were
liberated respectively from DNA upon binding of each
Mg2þ-coordinated antibiotic dimer. The polyelectrolyte
contributions to the free energy of MTA or MSK binding
to DNA were then calculated using these values and
Equation (4). At the 170 mM Naþ concentration (HPS
buﬀer) used in our experiments, we calculated that Gpe
was 0.39 kcalmol1 for MTA and 0.42 kcalmol1 for
MSK. These are rather modest contributions to the free
energy of binding (Table 1). The pKa of MTA is 5.0 (12),
so at pH7.4 it theoretically bears a 0.99 charge.
However, these calculations corresponded to free MTA,
while a crystallographic analysis of DNA–chromomycin
structure revealed that the Mg2þ-coordinated antibiotic
dimer has no electric charge (chromomycin bears the same
tricyclic core moiety as MTA and MSK) (14). For the
binding of an uncharged molecule to DNA, we may expect
the absence of a polyelectrolyte eﬀect (42). Nevertheless,
we observed such an eﬀect experimentally (Figure 3).
An explanation to this apparent discrepancy will be
presented in the Discussion section.
Isothermal titration calorimetry analysis ofMTA binding
to DNA
ITC was used to quantify the binding of an MTA–Mg2þ
complex to salmon testes DNA (Figure 4). An MTA–
Mg2þ complex was pre-formed in the syringe before
titration. Integration with respect to time of the heat
produced per serial injection of ligand to the DNA duplex
yields the corresponding isotherm (Figure 4A). These data
require correction for the heat associated with the addition
of ligand to buﬀer and of buﬀer to DNA, the latter being
negligible. Figure 4B shows that adding Mg2þ ions to a
DNA solution was associated with quite a low heat of
dilution (about 60 calmol1). The titration of Mg2þ-
coordinated MTA into buﬀer produced a curve (open
squares in Figure 4C) in which the heat signal was
dependent on the injected MTA concentration up to
Figure 2. Diﬀerential scanning calorimetry analysis of MTA and MSK
complexes with salmon testes DNA. Melting curves for DNA alone
and identical DNA solution in the presence of saturating amounts of
MTA or MSK (0.2mol antibiotic/mol DNA (bp)). The plots show the
excess of heat capacity (kcalmol1K1) as a function of temperature.
The area under the peaks provides direct estimates of the enthalpy for
DNA melting and the MTA–DNA and MSK–DNA complexes.
Table 1. Comparison of thermodynamic parameters for mithramycin A (MTA) and mithramycin SK (MSK) binding to salmon testes DNAa
Kobs (M
1) Gobs (kcalmol
1) Gpe (kcalmol
1) Gt (kcalmol
1) H (kcalmol1) TS (kcalmol1)
MTA 1.2 (0.3) 105 6.92 0.39 6.53 1.60 (0.32) 8.52
MSK 2.9 (1.0) 104 6.07 0.42 5.65 1.02 (0.33) 7.09
Enthalpy values were determined by DSC (means SD, from three independent experiments). aKobs (M1) is the binding constant for the interaction
of the antibiotics with salmon testes DNA in 170mM Naþ at 258C. Gobs is the binding free energy calculated from Gobs¼RT lnK. Gpe and
Gt are the polyelectrolyte and non-polyelectrolyte contributions to the binding free energy, evaluated at 170mM Na
þ.
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130mMMTA. This MTA concentration was equivalent to
that used to obtain an antibiotic-to-DNA ratio of 0.25 in
a titration experiment on DNA, while the heat signal
remained almost constant afterwards. Although the
signal dependence on ligand concentration has been
considered a consequence of self-association (32), the
titration of MTA on buﬀer (Figure 4C) can indicate that
the heat change reﬂects a composite eﬀect of the drug
dilution after its injection in the large cell together with the
re-formation of Mg2þ-coordinated MTA dimers. This
explanation is consistent with the presence of a plateau in
the titration, because this would be the sign once the
dimers were re-formed, after dilution in the larger cell
volume (compared to that of the syringe), the heat of
dilution remained almost constant (Figure 4C).
Furthermore, we carried out other titration experiments
to monitor the formation of MTA–DNA complexes
mediated by Mg2þ. For example, Figure S3 shows the
results of a representative experiment, in which an MTA
solution in HPS buﬀer was titrated into an MgCl2 solution
in the same buﬀer (see the legend of Figure S3). Several
inﬂections were observed during the ITC titration, which
depended on the MTA:Mg2þ molar ratio. The heats per
injectant became progressively more positive (Figure S3),
changing from 1.6 kcalmol1 at a magnesium-to-DNA
ratio of 1:4, to -1.2 kcalmol1 at a ratio of 1:2, which
corresponds to the formation of Mgþ2-coordinated MTA
dimers. Nevertheless, we cannot rule out that the heat
values obtained in these titrations were also indicative of
microaggregation of the antibiotic.
To obtain corrected binding isotherms (Figure 4D),
we subtracted each value obtained in the experiments
shown in Figure 4C from the raw MTA–DNA data
(Figure 4A). The ﬁtting of the corrected binding isotherm
to a single set of binding sites (see Materials and methods)
was used to obtain standard thermodynamic parameters
at 258C: H¼þ2.62 0.11 kcalmol1, Kobs¼ 7.4
(1.3) 104M1, n¼ 0.20 0.01 (i.e. a DNA:MTA
stoichiometry of 5). From these standard parameters,
we calculated G¼6.62 kcalmol1 and
TS¼þ9.24 kcalmol1 at 258C. The positive enthalpy
observed was in keeping with the value determined by
DSC (Table 1) and both ITC and DSC results agree
with the presence of Mg2þ-coordinated MTA dimers
(‘Complex II’ (17)) bound to DNA in solution. Our data
were also consistent with ﬂuorescence studies showing
entropically-driven binding of Mg2þ-coordinated MTA
dimers to DNA (12).
Evaluation of heat capacity changes involved in the binding of
mithramycins to DNA
The experimental characterization of heat capacity
changes (Cp) that may accompany binding presented
an insurmountable diﬃculty, as we only obtained repro-
ducible data by ITC using MTA in 170mM Naþ at 258C
(Figure 4). The main problem was the reproducibility of
some control (heat of dilution) experiments, which we
regard as a consequence of the necessary Mg2þ-coordi-
nated antibiotic dimerization coupled to binding along
the minor groove of DNA. Therefore, to obtain an
estimation of the heat capacity eﬀects in the formation of
DNA–MTA and DNA–MSK complexes, we undertook
calculations of the non-polar (hydrophobic) and polar
(hydrophilic) surfaces of MTA–DNA and MSK–DNA
complexes and their component molecules, which allowed
us to measure the binding-induced burial of speciﬁc
molecular surfaces (32).
Inspection of Figure 5 and Table 2 reveals that most
of the surface buried from exposure to solvent for the
interaction of either mithramycin is hydrophobic
rather than polar. Application of an empirical relationship
(see Materials and methods) provided a calculated
heat capacity change for the binding of MTA and
MSK (Table 2). Comparison of surface areas for the
native and complexed B-DNA (generated from
d(TCGCGA)2 duplexes) showed only a small reduction
in exposed DNA surface upon binding of either MTA or
MSK, suggesting the absence of large helical rearrange-
ments. From the Cp, determined from the surface area
buried by MTA or MSK (Table 2), we calculated the
hydrophobic component of the free energy of binding, by
using the relationship: Ghyd¼ 80 Cp (38), to be 9.53
and 9.04 kcalmol1 for MTA and MSK respectively
(Table 1).
If the Cp values (Table 2) were used together with the
enthalpies determined by DSC (Table 1), the Hb values
corrected by the heat capacity eﬀects at 258C would be
þ9.45 and þ8.31 kcalmol1 for MTA and MSK respec-
tively, which are higher than those presented in Table 1.
Furthermore, using these heat-capacity-corrected enthalpy
values the apparent binding constants for MTA and MSK
would be 7.3 105M1 and 2.4 105M1, respectively
in 170mM Naþ at 258C. These values are moderately
higher than those obtained using UV melting data and
DSC results, which assumed a zero Cp value (Table 1).
Figure 3. Salt dependence of MTA and MSK binding constants at
258C (Record’s plot (31)). The linear least-squares ﬁt of the data yields
slopes of 0.37 (MTA) and 0.40 (MSK), which are equivalent to the
number of ions released upon binding of MTA or MSK to DNA.
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The negative capacity changes causedH to become more
positive at lower temperatures, but the magnitude of such
higher H was largely compensated by an increased
entropic terms, thus the corrected G values for MTA
and MSK were 7.97 and 7.31 kcalmol1, respectively.
There is only a diﬀerence of 1 kcalmol1 between these
free energy values and those obtained from UV melting
experiments, which considered a zero Cp (Table 1).
Moreover, for MTA these corrected enthalpy and binding
constant were also higher than the H and Kb obtained
directly by ITC, see above.
Competitiondialysis assayofMTAandMSKbinding toDNA
A competition dialysis assay (27) was used to study the
MTA- and MSK-binding preferences for DNAs of
Figure 4. Isothermal titration curves of MTA binding to salmon testes DNA at 258C. (A) Titration of a Mg2þ–MTA complex in HPS buﬀer
(pre-formed in the syringe of the ITC apparatus) into DNA in the same buﬀer solution without added Mg2þ. ITC raw data are shown in the top
panel, while the lower panel shows the uncorrected binding isotherm. (B) Heat of dilution of an MgCl2 solution titrated into a DNA solution in HPS
buﬀer. The distribution of the heats of dilution of Mg2þ corresponds to a H  60 calmol1. (C) Heat change induced in an ITC experiment by
adding Mg2þ–MTA complexes into buﬀer in the absence of DNA (open squares). The panel also shows the uncorrected isothermal titration curve of
the titration of Mg2þ-MTA complex into DNA (black squares) redrawn from (A). (D) Corrected binding isotherm resulting from integration with
respect to time, with correction for the measurements presented in (B and C) (see also Figure S3). The heats obtained for each injection in (C) were
subtracted from the corresponding raw value (open squares) in the same panel.
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various nucleotide compositions. This experimental
approach allowed us to calculate apparent binding
constants of mithramycins to C/G-rich DNAs, which
cannot be studied using UV thermal denaturation,
because their high Tm hinders accurate measurement. An
evaluation of the binding to DNAs of diverse nucleotide
compositions was used to characterize the diﬀerences in
the binding of MTA and MSK to diﬀerent DNA
sequences (Figure 6). Both antibiotics bind more tightly
to M. lysodeikticus DNA (72% CþG) than to salmon
testes DNA (42% CþG), while the binding of MTA to
the strictly alternating CG-tracts found in poly[d(G-C)2] is
higher than that of MSK (Figure 6). The binding of both
ligands to poly[d(I-C)2] was rather weak, as expected,
since it does not contain the guanines required for speciﬁc
binding.
The Kapp for the various DNAs, calculated from the
competition dialysis assays, are shown on the right side in
Figure 6. These values can be compared with the binding
to salmon testes DNA we determined by other methods.
The MTA and MSK binding constants are slightly
diﬀerent from those obtained by UV thermal denaturation
(cf. Figure 6 and Table 1), reﬂecting the presence of a
small heat capacity eﬀect, which was not considered when
the binding data, determined at the Tm, were extrapolated
to 258C by using Equation (6). MTA binding to DNA was
entropically driven (Table 1), with enthalpy values ranging
from þ1.60 kcalmol1 obtained by DSC at the Tm, to
þ2.62 kcalmol1 obtained by ITC (Figure 3). The
comparison of these values reveals that any heat capacity
eﬀect would be relatively small, since there was a
diﬀerence of only 1 kcalmol1 between the H deter-
mined at 91.08C by DSC and the direct measurement at
258C by ITC.
DISCUSSION
Thermodynamic analysis of drug binding to DNA oﬀers
valuable insights into the molecular forces involved in
complex formation that cannot be obtained by structural
studies alone (23,44). The interpretation of thermody-
namic parameters may contribute to the design of new
DNA-targeted drugs. We present the ﬁrst calorimetric
study on the binding of natural minor-groove ligands to
C/G-rich regions in DNA. So far, the binding in the minor
groove of AT-rich sequences has been characterized
thermodynamically (24,44), although some features of
the binding to C/G-rich DNA are also known (22).
Binding to C/G-rich DNA has been addressed for
intercalating agents (23,45), yet some of these agents
also bind along the minor groove in the vicinity of the
intercalating site in DNA tracts of diverse sequences
(40,41,46).
Although the H values obtained by DSC or ITC diﬀer
from those obtained by spectroscopic techniques (12) they
are consistent with the view that positive enthalpy is
involved in the binding of Mg2þ-coordinated MTA dimers
in the minor groove of DNA. Binding of MTA and MSK
to DNA is clearly entropically driven (Table 1), and the
positive sign of both H and S can be considered
hallmarks of a predominantly hydrophobic binding
reaction (23,47).
It is interesting to compare the thermodynamic
proﬁle of the MTA binding to DNA described here with
previous determinations of the enthalpy of binding by
Table 2. Determination of the surface area burial for mithramycin A–DNA and mithramycin SK–DNA complexesa
Mithramycin A Mithramycin SK
Non-polar surface Polar surface Total surface Non-polar surface Polar surface Total surface
DNA–antibiotic
complex
1 588 1 657 3 245 1 559 1 657 3 216
DNA–unboundb 920 1 608 2 528 920 1 608 2 528
Mgþ2-coordinated
antibiotic dimer
1 359 777 2 136 1 302 759 2 061
Induced changes Anp¼691 Ap¼728 A¼1419 Anp¼663 Ap¼710 A¼1 373
Calculated Cp
c 119 (28) cal mol1 K1 113 (27) calmol1K1
Ghyd
d 9.53 (0.28) kcalmol1 9.04 (0,27) kcalmol1
aArea calculations (A˚2) were carried out using NACCESS program (35).
bAn ideal B-DNA structure of d(TCGCGA)2 sequence, generated by the program 3DNA (34).
cHeat capacity change were computed from the induced changes in the surface area burials as described in the Materials and methods section.
dGhyd¼ 0 (20) Cp (38).
Figure 5. Molecular (water)-accessible surface for the bound MTA
molecule in the minor groove of a B-DNA of d(TCGCGA)2 sequence.
Structural coordinates were taken from an NMR complex (16), PDB
entry 146D. The ﬁgure was generated with the Chimera program (43).
The right panel shows a detailed view of the region selected on the left
panel. It also includes the structurally equivalent MSK atoms. This
view highlights the diﬀerent side-chains bound to the aglycone
C-3 atoms in MTA (carbon atoms in blue) and MSK (carbon atoms
in yellow). Compared to MTA, the shorter length of the MSK side
chain restrains its possibilities of hydrogen bonding to DNA.
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spectroscopic titration and ﬂuorescence (12,17).
In spectroscopic studies, positive enthalpy was also
observed under conditions consistent with the formation
of Mg2þ-coordinated MTA dimers. In those experiments,
the enthalpy of binding (H¼þ5.1 kcalmol1) was
estimated by application of the van’t Hoﬀ relationship
to the spectroscopic data (12,17). This value is about
2-fold higher than the enthalpy we obtained directly using
ITC at 258C (H¼þ2.6 kcalmol1). These enthalpy
values were measured under quite diﬀerent ionic strength
conditions—higher in our experiments—(cf. Table 1,
Figures 4 and 6, and Ref. (12)). The diﬀerences in the
calculated H may be attributed to an ionic dependence
of the enthalpy of binding (48). Our observation that the
binding enthalpies determined by van’t Hoﬀ’s analysis
were higher than those reported using direct ITC
measurements is consistent with previous reports [(48)
and references therein]. Besides, the comparison of these
H reveals the presence of heat capacity changes (Cp),
which we determined from the solvent-accessible areas
in drug–DNA complexes (Table 2). These changes
indicate that H estimates for MTA binding to DNA
are temperature dependent, a situation sometimes
neglected in van’t Hoﬀ’s analyses of drug–DNA interac-
tions obtained from spectroscopic data (49). For MTA,
correcting the Hb obtained by DSC, using the calculated
Cp, renders an enthalpy, at 258C, higher than its
value determined directly by ITC, which points to intrinsic
diﬃculties in measuring the DNA binding constants
for Mg2þ-coordinated antibiotics by this technique.
The Mg2þ requirement for the binding of mithramycin
and related antibiotics to DNA has long been known [(15)
and references therein] and the presence of a dication is
essential for the formation of the dimers that bind to
DNA (12). The presence of Mg2þ in the binding buﬀer
merits further consideration not only because of the eﬀects
on the ionic strength, but also because of the direct
binding (condensation) of the dication to the
deoxyribonucleic acids (50). The eﬀect of multivalent
cations on the DNA–ligand interactions is greater than
expected on the basis of their contribution to the ionic
strength (50,51). Our experiments were performed at
170mM Naþ, which may facilitate solubility and reduce
possible self-association of the antibiotic, while the
concentrations of MgCl2 varied depending on the
technique used (see Materials and Methods). In all cases,
however, the ﬁnal concentration was always kept below
1mM in the presence of DNA. Therefore, Mg2þ eﬀects
through direct binding to DNA were minimized, while the
relative contribution of MgCl2 to the ionic strength was
insigniﬁcant. To analyse the eﬀect of magnesium it is
impossible to carry out binding experiments with and
without dications, because they are necessary for mithra-
mycin binding to DNA. Indeed, the presence of magne-
sium in the ITC titration of MTA into DNA required us
to distinguish between the ‘heat of dilution of the drug’
and the dimerization of MTA when both the antibiotic
and the dication became diluted after injecting into the
large ITC cell. Addressing this particular issue, we
obtained reproducible results for MTA only (Figures 4
and S3).
A small favourable contribution to free energy of
binding was found to arise from the polyelectrolyte
eﬀect (Figure 3 and Table 1), although Mg2þ-coordinated
mithramycins are uncharged species. In order to reconcile
this apparent discrepancy, we considered that ion release
is a consequence of changes in the distance between the
phosphates upon binding, due to a widening of the minor
groove, which can alter the number of cations associated
with each phosphate. We base this interpretation on the
analysis of the salt dependence of the binding of
uncharged intercalators to DNA (42). This analysis
describes the ion release upon binding as a consequence
of changes in the distance between the phosphates, which
would alter the fraction of cations associated per
phosphate. The eﬀect for minor-groove-binding ligands
must be lower, as we observed (Figure 3). In line with
this explanation, NMR results indicate that binding of
Mg2þ-coordinated drugs can involve a wider minor
groove (13,16). The entropy that accompanies the release
of groove-bound ions upon binding of the oligosaccharide
moieties into the minor groove also contributes to the free
energy of binding (52).
We have determined the hydrophobic transfer free
energies (Ghyd) from changes of the solvent accessibility
areas upon drug binding (Table 2 and Figure 5) because
Cp could not be measured experimentally. For Mg
2þ-
coordinated MTA or MSK dimers, Ghyd is large and
‘favourable’ (negative), as a consequence of various
hydration contributions to binding in the minor groove,
which include the displacement of the ‘spine of hydration’
(22,24,25,32), and may comprise a dehydration eﬀect
produced by Mg2þ cations. These values are larger than
the observed free energy of binding (cf. Tables 1 and 2).
Therefore, they are enough to counterbalance the unfa-
vourable entropic cost of forming DNA–mithramycin
complexes. A negative heat capacity change causes H to
become more positive at lower temperatures, which may
exaggerate the entropic driving force for binding. When
Figure 6. Competition dialysis experiments using MTA and MSK and
various DNAs. Data correspond to experiments performed in triplicate
(meansSD). Values to the right are the apparent binding constants
for the displayed DNAs, calculated, as described in the Materials and
Methods section, using the bound antibiotic concentrations [Cbound]
shown in the ﬁgure.
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the calculated Cp values (Table 2) were used together
with thermodynamic parameters derived from UV melting
plus DSC analyses (Table 1), the derived H values were
larger, see the Results section, yet the free energy of
binding (G) changed moderately due to entropy/
enthalpy compensation. Besides, it is evident that using
either the theoretically derived Cp (Table 2) or consider-
ing the 1 kcalmol1 diﬀerence between the H for
MTA, obtained from DSC (at melting temperature) and
ITC (at 258C) experiments (Table 1 and Figure 4), renders
small negative heat capacity changes. These negative heat
capacity changes are consistent with the hydrophobic
interactions, which are the major driving forces for the
formation of DNA–mithramycin complexes. NMR stu-
dies indicate local changes in the C/G-rich binding site
that consist of the presence of A-DNA sugar puckers and
glycosidic torsion angles (13,16), which may induce the
enhanced reactivity of some bases in chemical footprinting
(11). A small local transition to A-DNA conformation
upon drug binding might result in some water release since
A-DNA can be considered a dehydrated form of DNA
(53). Another factor that would involve positive entropy
of binding is the release of counterions following this local
conformational change and the widening of the minor
groove. The oligosaccharide moieties (which are the same
in MTA and MSK) participate in the entropic component
of binding by disturbing both the water spine in the minor
groove around AT base pairs (53) and the other DNA
solvation shells, which should be less sensitive to sequence
(22). The consequence would be a net favourable
contribution to the free energy of binding (54). As
mentioned above, our results are in keeping with that a
large contribution of the hydrophobic transfer (Ghyd)
might overwhelm the unfavourable contributions from
changes in conformation and the entropic cost of forming
a bimolecular complex (23,44), thereby a favourable ﬁnal
G is achieved.
Diﬀerences in the free energy of binding for MTA and
MSK, other than those provided by the hydrophobic
contributions to the free energy of binding and the small
polyelectrolyte contribution (Table 1), arise from direct
molecular interactions in the C/G-rich binding sites. These
include hydrogen bonds, van der Waals interactions and
other weak forces (32,40), which would participate in the
higher MTA-binding aﬃnity (Table 1). A preferred MTA-
binding site in DNA contains at least two contiguous C/G
base pairs (4,15). However, there are discrepancies on the
exact arrangement of the bases within the preferred
binding site and the DNA sequences in their vicinity,
since MTA extends its binding in the minor groove about
5–6 bp (Figure S1) and (4,16). We detected diﬀerences in
the binding preferences of MTA and MSK to DNA of
diﬀerent CþG-content by competition dialysis (Figure 6).
Both antibiotics failed to interact signiﬁcantly with
poly[d(I-C) 2], indicating that sequence-selective interac-
tion is achieved via the binding of the chromophore to the
amino group of guanines (4,11,13,15,16). However, some
sequences containing guanines, for example G/A-rich
tracts, do not bind MTA (11,55). Speciﬁc recognition in
the minor groove of C/G-rich DNA by MTA involves
direct hydrogen bonding between the aglycone C8
hydroxyl oxygens of Mg2þ-coordinated antibiotic dimers
(Figure 1) and the 2-amino of guanines (13,16). MTA and
MSK contain the same tricyclic core moiety and
oligosaccharide side chains, but they diﬀer in the side
chain at C-3. This chain is longer in MTA and bears a
higher number, and diﬀerent arrangement, of potential
donors and acceptors of hydrogen bonds (Figure 1).
Hence, a higher (more negative) free binding energy (G)
for MTA is consistent with the formation of extra
hydrogen bonds. The oligosaccharide moieties of the
mithramycins are the same. They are involved in the
binding within the DNA minor groove, forming equiva-
lent intermolecular contacts with the sugar-phosphate
backbone (4,13).
The higher binding constant determined for MTA is
consistent with its capacity to displace Sp1 protein from its
putative C/G-rich binding sites at concentrations below
those at which MSK does this (10). The comparison
between MTA and MSK binding to DNAs of diverse
CþG content (Figure 6) highlights the fact that small
substitutions in naturally occurring DNA-binding mole-
cules have signiﬁcant eﬀects on intermolecular interac-
tions, which for mithramycin analogues appears to result
in diﬀerent biological properties (20).
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